Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
Japan’s Central Social Insurance Medical Council (Chuikyo) on May 13 approved insurance coverage for digital therapeutics developed by Susmed for insomnia and by Shionogi for ADHD, with reimbursements set to begin on June 1. The reimbursement price for Susmed’s insomnia…
To read the full story
Related Article
- Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
REGULATORY
- CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
August 5, 2026
- Outgoing MHLW Pharmacy Chief Eyes AI as Next Frontier for Drug Regulation
August 4, 2026
- Takeda’s Orzeyful Inches Closer to Japan Approval as 1st NT1 Drug
August 4, 2026
- MHLW Gives Fuel Priority to Drug Deliveries in Quake-Hit Kumamoto
August 4, 2026
- Unami Tapped as Japan’s New Top Finance Bureaucrat
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…